Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 4/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL640241 | 0.93 | F2R (0.59) | F2RCNR1TMEM97SMN1; SMN2POLB | |
| SCHEMBL641322 | 0.92 | F2R (0.60) | F2RCNR1TMEM97SMN1; SMN2POLB | |
| SCHEMBL641719 | 0.91 | F2R (0.59) | F2RCNR1TMEM97SMN1; SMN2POLB | |
| SCHEMBL642061 | 0.89 | F2R (0.59) | F2RCNR1TMEM97SMN1; SMN2POLB | |
| SCHEMBL643047 | 0.88 | F2R (0.64) | F2RCNR1TMEM97SMN1; SMN2POLB | |
| SCHEMBL642996 | 0.87 | F2R (0.57) | F2RCNR1TMEM97SMN1; SMN2POLB | |
| SCHEMBL641385 | 0.87 | F2R (0.57) | F2RCNR1TMEM97POLBGRM5 | |
| SCHEMBL643745 | 0.87 | F2R (0.55) | F2RCNR1TMEM97SMN1; SMN2POLB | |
| SCHEMBL643708 | 0.87 | F2R (0.62) | F2RCNR1TMEM97SMN1; SMN2POLB | |
| SCHEMBL643491 | 0.86 | CNR1 (0.56) | F2RCNR1TMEM97GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| EP-2227466-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-15 | — | — | EP | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009068214-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | F2R 698/4885CNR1 454/4885TMEM97 1110/4885 |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | F2R 698/4885CNR1 454/4885TMEM97 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.